BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice

Experimental Parasitology

Volumn 94, Issue 1, 2000, Pages 33-41

  Streit, Judy A ^a,c   Recker, Thomas J ^a   Donelson, John E ^a   Wilson, Mary E ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; PROTOZOAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; IMMUNIZATION; LEISHMANIA CHAGASI; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SPLEEN CELL;

ANIMALIA; LEISHMANIA DONOVANI CHAGASI; MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; PROTOZOA;

EID: 0033959560     PISSN: 00144894     EISSN: None     Source Type: Journal    
DOI: 10.1006/expr.1999.4459     Document Type: Article

References (60)

1. Abdelhak S., Louzir H., Timm J. Recombinant BCG expressing the Leishmania surface antigen gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology. 141:1995;1585-1592.
2. Afonso L. C. C., Scharton T. M., Leda Vieira, Wysocka M., Trinchieri G., Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science. 263:1994;235-237.
3. Aldovini A., Young R. A. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature. 351:1991;479-482.
4. Alexander J. A radioattenuated Leishmania major vaccine markedly increases the resistance of CBA mice to subsequent infection with Leishmania mexicana mexicana. Transactions of the Royal Society of Tropical Medicine and Hygiene. 76:1982;646-649.
5. Alexander J., Kaye P. M. Immunoregulatory pathways in murine leishmaniasis: Different regulatory control during Leishmania mexicana mexicana and Leishmania major infections. Clinical and Experimental Immunology. 61:1985;674-682.
6. Antunes C. M. F., Mayrink W., Magalhaes P. A., Costa C. A., Melo M. N., Dias M., Michalick M. S., William S. P., Lima A. O., Vieira J. B., Schettini A. P. M. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. International Journal of Epidemiology. 15:1986;572-580.
7. Badaro R., Jones T. C., Lorenco R. A prospective study of visceral leishmaniasis in an endemic area of Brazil. Journal of Infectious Diseases. 154:1986;639-649.
8. Champsi J., McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infection and Immunity. 52:1988;3272-3279.
9. Chaparas S. D. The immunology of mycobacterial infections [Review]. Critical Reviews of Microbiology. 9:1982;139-197.
10. Connell N. D., Medina-Acosta E., McMaster W. R., Bloom B. R., Russell D. G. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proceedings of the National Academy of Sciences USA. 90:1993;11473-11477.
11. Convit J., Castellano P. L., Rondon A. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet. 1987;401-404.
12. Emmrich F., Thole J., van Embden J., Kaufmann S. H. A recombinant 64 kDalton protein of Mycobacterium bovis bacillus Calmette-Guerin specifically stimulates human T4 clones reactive to mycobacterial antigens. Journal of Experimental Medicine. 163:1986;1024-1029.
13. Flesch I. E., Hess J. H., Huang S. Early IL-12 production by macrophages in response to mycobacterial infection depends on interferon-γ and tumor necrosis factor α Journal of Experimental Medicine. 181:1995;1615-1621.
14. Fortier A. H., Mock B. A., Meltzer M. S., Nacy C. A. Mycobacteium bovis BCG-induced protection against cutaneous and systemic Leishmania major infections of mice. Infection and Immunity. 55:1987;1707-1714.
15. Ghalib H. W., Whittle J. A., Kubin M. IL-12 enhances Th1-type responses in human Leishmania donovani infections. Journal of Immunology. 154:1995;4623-4629.
16. Gorczynski R. M. Nature of resistance to leishmaniasis in experimental rodents. Developmental and Comparative Immunology. 6:1982;199-207.
17. Greenblatt C. L. Cutaneous leishmaniasis: The prospects for a killed vaccine. Parasitology Today. 4:1988;53-54.
18. Greenblatt C. L. The present and future of vaccination for cutaneous leishmaniasis. Mizranhi A., Hertman I., Klinberg M. A., Kohn A., New Developments with Human and Veterinary Vaccines. 1980;259-285 A. R. Liss, New York.
19. Handman E., El-On J., Spira D. T., Zuckerman A., Greenblatt C. L. Protection of C3H mice against L. tropica by a nonliving antigen preparation. Journal of Protozoology. 24:1977;20A.
20. Handman E., Mitchell G. F. Immunisation with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis. Proceedings of the National Academy of Sciences USA. 82:1985;5910-5914.
21. + lymphocytes in vivo during healing and progressive murine leishmaniasis. Proceedings of the National Academy of Sciences USA. 88:1991;7011-7015.
22. Heinzel F. P., Schoenhaut D. S., Rerko R. M., Rosser L. E., Gately M. K. Recombinant interleukin 12 cures mice infected with Leishmania major. Journal of Experimental Medicine. 177:1993;1505-1509.
23. + T-cell subset responses during murine leishmaniasis. Parasitology Today. 10:1994;190.
24. Ho M., Siongok T. K., Lyerly W. H., Smith D. H. Prevalence and disease spectrum in a new focus of visceral leishmaniasis in Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene. 76:1982;741-746.
25. Holaday B. J., Sadick M. D., Wang Z. Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines. Journal of Immunology. 147:1991;1653-1658.
26. Howard J. G., Nicklin S., Hale C., Liew F. Y. Prophylactic immunization against experimental leishmaniasis: I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection. Journal of Immunology. 129:1982;2206-2212.
27. Ibanez C. F., Affranchino J. L., Macin R. A. Multiple Trypanosoma cruzi antigens containing tandemly repeated amino acid sequence mofits. Molecular and Biochemical Parasitology. 30:1988;27-34.
28. Kaye P. M., Curry A. J., Blackwell J. M. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. Journal of Immunology. 146:1991;2763-2770.
29. Krueger M. R., Tames D. R., Mariano M. Expression of NO-synthase in cells of foreign body and BCG-induced granulomata in mice: Influence of L-NAME on the evolution of the lesion. Immunology. 95:1998;278-282.
30. Lafaille J. J., Linss J., Krieger M. A., Souto-Padron T., de Souza W., Goldenberg S. Structure and expression of two Trypanosoma cruzi genes encoding antigenic proteins bearing repetitive epitopes. Molecular and Biochemical Parasitology. 35:1989;127-136.
31. Lagranderie M. R., Balazuc A. M., Deriaud E., Leclerc C. K., Gheorghiu M. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infection and Immunity. 64:1996;1-9.
32. Liew F. Y., Hale C., Howard J. G. Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunzation prevents the induction of protective immunity against fatal Leishmania major infection. Journal of Immunology. 135:1985;2095-2101.
33. + T cells in leishmaniasis. Immunology Today. 40:1989;40-45.
34. Mayrink W., Da Costa W. P., Magalhaes P. A., Melo M. N., Dias M., Oliviera Lima A., Michalick M. S. M., Ferreira Carvalho E., Barros G. C., Sessa P. A. An experimental vaccine against American dermal leishmaniasis: Experience in the state of Espirito Santo, Brazil. Annals of Tropical Medicine and Parasitology. 79:1985;259-269.
35. McElrath M. J., Murray H. W., Cohn Z. A. The dynamics of granuloma formation in experimental visceral leishmaniasis. Journal of Experimental Medicine. 167:1988;1927-1937.
36. Melby P. C. Experimental leishmaniasis in humans: Review. Review of Infectious Diseases. 13:1991;1009-1017.
37. Murray H. W., Rubin B. Y., Rothermel C. D. Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes: Evidence that interferon-γ is the activating lymphokine. Journal of Clinical Investigation. 72:1983;1506-1510.
38. Murray A., Winter N., Lagranderie M. Expression of Escherichia coli-B-lactamase in Mycobacterium bovis BCG using an expression system isolated from Mycobacterium paratuberculosis which induced humoral and cellular immune responses. Molecular Microbiology. 6:1992;3331-3342.
39. Murray H. W., Hariprashad J., Coffman R. L. Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. Journal of Experimental Medicine. 185:1997;867-874.
40. Nadim A., Javadian E. Leishmanization in the Islamic Republic of Iran. Walton B., Wijeyaretne P. M., Modabber F., Research on Control Strategies for the Leishmaniasis. 1988;336-339 International Development Research Centre, Ottawa.
41. Naggan L., Gunders A. E., Michaeli D. Follow-up study of a vaccination Programme against cutaneous leishmaniasis. II. Vaccination with a recently isolated strain of L. tropica from Jericho. Transactions of the Royal Society of Tropical Medicine and Hygiene. 66:1972;239-243.
42. Nozaki Y., Hasegawa Y., Ichiyama S., Nakashima I., Shimokata K. Mechanism of nitric oxide-dependent killing of Mycobacterium bovis BCG in human alveolar macrophages. Infection and Immunity. 65:1997;3644-3647.
43. Pappas M. G., Oster C. N., Nacy C. A. Intracellular destruction of Leishmania tropica by macrophages activated in vivo with Mycobacterium bovis strain BCG. Advances in Experimental Medicine and Biology. 162:1983;425-431.
44. Pearson R. D., Steigbigel R. T. Mechanism of lethal effect of human serum upon Leishmania donovani. Journal of Immunology. 25:1980;2195-2201.
45. Preston P. M., Dumonde D. C. Experimental cutaneous leishmaniasis. V. Protective immunity in subclinical and self-healing infection in the mouse. Clinical and Experimental Immunology. 23:1976;126-138.
46. Rachamim H., Jaffe C. L. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. Journal of Immunology. 150:1993;2322-2331.
47. Russell D. G., Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. Journal of Immunology. 140:1988;1274-1279.
48. Scott P. A., Farrell J. P. Experimental cutaneous leishmaniasis: Disseminated leishmaniasis in genetically susceptible and resistant mice. American Journal of Tropical Medicine and Hygiene. 31:1982;230-238.
49. Scott P., Natovitz P., Coffman R. L., Pearce E., Sher A. Immunoregulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. Journal of Experimental Medicine. 168:1988;1675-1684.
50. Smrkovski L., Larson C. L. Effect on treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. Infection and Immunity. 16:1977;249-257.
51. Squires K. E., Schreiber R. D., McElrath M. J., Rubin B. Y., Anderson S. L., Murray H. W. Experimental visceral leishmaniasis: Role of endogenous interferon-gamma in host defense and tissue granulomatous response. Journal of Immunology. 143:1989;4244-4249.
52. Stauber L. A. Host resistance to the Khartoum strain of Leishmania donovani. Rice Institute Pam. 45:1958;80.
53. Stover C. K., de la Cruz, Fuerst T. R., Burlein J. E., Benson L. A., Bennett L. T., Bansol G. P., Young J. F., Lee M. H., Hatfull G. F., Snapper S. B., Barletta R. G., Jacobs W. R. Jr., Bloom B. R. New uses of BCG for recombinant vaccines. Nature. 351:1991;456-460.
54. Stover C. K., Bansal G. P., Hanson M. S. Protective immunity elicited by recombinant Bacille Calmette-Guerin expressing outer surface protein A lipoprotein: A candidate lyme disease vaccine. Journal of Experimental Medicine. 178:1993;197-209.
55. Thatte J., Rath S., Bal V. Analysis of immunization route-related variation in the immune respone to heat-killed Salmonella typhimurium in mice. Infection and Immunity. 63:1995;99-103.
56. van Vugt E., Verdaasdonk M. A. M., Beelen R. H., Kamperdijk E. W. A. Induction of an increased number of dendritic cells in the peritoneal cavity of rats by intraperitoneal administration of Bacillus Calmette-Guerin. Immunobiology. 186:1992;230-240.
57. White A. C. Jr., McMahon-Pratt D. Prophylactic immunization against experimental Leishmania donovani infection by use of a purified protein vaccine. Journal of Infectious Diseases. 161:1990;1313-1314.
58. Wilson M. E., Young B. M., Paetz Anderson K. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infection and Immunity. 63:1995;2062-2069.
59. Wilson M. E., Sandor M., Blum A. M. Local suppression of interferon-gamma in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. Journal of Immunology. 156:1996;2231-2239.
60. Yang D. M., Fairweather N., Button L. L., McMaster W. R., Kahl L. P., Liew F. Y. Oral Salmonella typhimurium (Aro A-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. Journal of Immunology. 145:1990;2281-2285.